About Us

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Our lead clinical candidate, frevecitinib (KN-002), is a novel and non-invasive anti-inflammatory to treat all patients with severe asthma. With our founding investors, 5AM Ventures, Atlas Venture and Gimv, we are pursuing a patient-focused approach to build a leading respiratory therapeutics company.

Robert Clarke, PhD
Chief Executive Officer / Board Member / Co-Founder

Roger Heerman, MBA
Chief Business/Operating Officer / Co-Founder

Frazer Morgan
Chief Development Officer / Co-Founder

Anesa Moyer
Vice President of Clinical Operations

Nayna Govind
Vice President, CMC

Kevin Bitterman, Ph.D.
Partner, Atlas Venture

Henry Stusnick
RA Capital Management

Daniela Begolo
EQT Life Sciences

Elliot Levy, M.D.
Venture Partner, 5AM Ventures

Bram Vanparys, MBA, Ph.D.
Partner, Gimv

Thomas King, MBA
Chair

Robert Clarke, Ph.D.
CEO, Kinaset Therapeutics

Ian Adcock, Ph.D.
Professor of Respiratory Cell & Molecular Biology, Imperial College

Gary Burgess M.B., ChB MMed(Int)(Stell) MFPM
Medical Consultant, GCB Clinical Consulting

Kristen Slaoui, Ph.D.
Chief Corporate Development Officer, Galderma

Dave Singh, M.D.
Professor, The University of Manchester